Recommended Free Tools
Outpace Bio announced a $144 million Series B on August 1, 2024, led by RA Capital Management. The company said it would use the financing to move engineered T-cell candidates toward early clinical proof of concept in solid tumors and expand its pipeline and platform. Outpace reported that the round brought its total capital raised to approximately $200 million at the time.
What the $144 million round means—and what it does not tell us
The financing was a private company funding round, not evidence that a treatment works or is available to patients. The amount and lead investor are company-reported details from Outpace’s August 2024 announcement. The reported total capital raised is also a figure from the company at that time, not a current balance sheet or a measure of how long the funding will last.
A round size by itself does not establish the company’s valuation, investor ownership, remaining cash, or development runway. The announcement’s stated purpose was to support early clinical development and platform expansion; it did not turn the programs into approved medicines.
Outpace’s investor RA Capital Management described the solid-tumor challenge this way in the announcement: “Existing cell therapies have fallen short in treating solid tumors, offering limited and transient responses.” That is an investor’s characterization of the field, not clinical evidence about Outpace’s candidates.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallOutdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware match#1 Best Overall
How Outpace says its cell-engineering platform works
Outpace describes its approach as AI-powered protein design applied to engineered immune cells. Its platform names refer to different design goals: OUTSPACER for CAR geometry and tumor-cell recognition; OUTSMART for locally produced designed cytokines; OUTLAST for cell persistence and regulation; OUTMATCH for receptor pairing; OUTDRIVE for in-vivo delivery; and OUTSAFE for a safety switch. These are company descriptions of intended mechanisms, not independently established clinical benefits.
OPB-101 was the financing announcement’s lead program
In August 2024, Outpace identified OPB-101 as its lead candidate. The program paired a mesothelin-targeted CAR with the company’s OUTSMART, OUTLAST, OUTSPACER, and OUTSAFE technologies. The initial population named in the financing announcement was people with advanced platinum-resistant epithelial ovarian, fallopian-tube, or primary peritoneal cancer.
Rank #2
Outpace said at the time that OPB-101 was on track for IND clearance and first dosing in 2025. That was a forward-looking company target, not confirmation that either milestone occurred. In a November 2024 update, the company described tumor-control and persistence findings in xenograft mouse models as preclinical and said initial patient dosing was targeted for 2025. It also reported activity at treatment doses as low as 50,000 cells in stringent in-vivo models. That figure concerns company-reported preclinical models; it is not a patient dose or a clinical result. Mouse-model findings do not establish safety or efficacy in people.
What the OPB-101 study listing establishes
The National Cancer Institute lists an Outpace-sponsored OPB-101 study, NCT07030907, as an active Phase I study. Its title is “A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer.” The NCI listing describes a Phase 1a/b evaluation intended to assess safety and identify an appropriate dose, and includes eligibility information with a link to the ClinicalTrials.gov record.
Free tools Windows power users keep installed
One-click scans. No signup required.
An active Phase I listing indicates that the study is investigational; it is not evidence of an approved treatment. The cited listing does not confirm that participants have been dosed or provide patient-level safety or efficacy outcomes. No independent clinical efficacy statistic is established by the cited materials.
Outpace’s disclosed pipeline has since broadened
Outpace’s current science-page lineup differs from the focus of its 2024 financing announcement. The company now identifies OPB-201 as its lead early-clinical program and lists OPB-401 at candidate-nomination stage. The programs use distinct modalities and address different targets and cancers, so they should not be treated as interchangeable versions of OPB-101.
| Program | Modality and target | Indication described | Stage or evidence described |
|---|---|---|---|
| OPB-101 | Engineered T-cell therapy combining a mesothelin-targeted CAR with OUTSMART, OUTLAST, OUTSPACER, and OUTSAFE, according to Outpace’s 2024 financing announcement | Advanced platinum-resistant epithelial ovarian, fallopian-tube, or primary peritoneal cancer in the announcement; the NCI study listing specifies platinum-resistant ovarian cancer | Outpace’s November 2024 update described xenograft mouse findings as preclinical. The NCI lists an active Phase I study; its listing does not establish participant dosing or outcomes. |
| OPB-201 | Autologous PRAME TCR-T, according to Outpace’s current science page | Endometrial, ovarian, and other solid tumors, according to Outpace | Identified by Outpace as its lead early-clinical program; a more specific stage is not stated on the cited page. |
| OPB-401 | In-vivo CD19xCD20 CAR-T, according to Outpace’s current science page | B-cell lymphomas | Candidate-nomination stage, according to Outpace. |
What readers can reasonably conclude
The $144 million Series B gave Outpace reported financing to pursue its cell-therapy development plans, but the amount does not answer whether any candidate will work or reach patients. The strongest evidence described for OPB-101 remains preclinical, alongside an active Phase I study listing whose cited information does not report dosing or patient outcomes. Outpace’s more recently disclosed lead is OPB-201, while OPB-401 is earlier in development.
Quick Recap
Best Value
Rank #4
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
